Illumina opens genomics lab in Melbourne Biomedical Precinct

Illumina Australia Pty Ltd

Tuesday, 23 November, 2021

Illumina opens genomics lab in Melbourne Biomedical Precinct

Genomics company Illumina has announced the opening of a new, fully equipped laboratory to help Australian researchers and entrepreneurs make significant scientific breakthroughs in areas such as infectious disease, oncology, genetic disease and agriculture.

Known as the Illumina Innovation Collective and based in the Melbourne Biomedical Precinct, the lab will make available the latest in DNA sequencing, array platforms and data analysis tools, all supported by specialist scientific expertise to enable clinicians and researchers to not only understand the genome, but also to fully tap into its power.

“Genomic discoveries offer new treatments and fresh hope to the patients of tomorrow as well as novel solutions for our farming communities,” said Gretchen Weightman, Illumina Vice President and General Manager of Asia Pacific and Japan.

“During our early years, Illumina pioneered technology that could see into the genome. Since then, we have endeavoured to make the genome more accessible to ensure that the extraordinary potential of these scientific breakthroughs has a truly global reach.

“Our investment is a testament to the strength and breadth of the unique talent and culture of innovation that can be found in Australia.”

The Illumina Innovation Collective goal is to support at least a half a dozen Australian research projects concurrently. It is the first genomics lab in Australia where Illumina’s training specialists, lab scientists, clinical liaison officers and medical affairs teams are working shoulder to shoulder with genomics leaders, healthcare professionals and patient communities to fully realise the potential of genomics.

The lab will also host Illumina for Startups Australia, which is focused on creating an innovation ecosystem for the genomics industry by partnering with leading venture capital investors and entrepreneurs to create, launch and grow genomics startups in Australia. Illumina for Startups initiatives also include Illumina Accelerator, founded in 2014, and Sequoia Capital China Intelligent Healthcare Genomics Incubator, powered by Illumina, announced in 2021.

“We are looking forward to partnering with the vibrant entrepreneurial and investor ecosystem in Australia by dedicating advanced technologies, genomics expertise, business guidance and networks to accelerate innovation and startups across the region,” said Dr Emma Ball, Head of Illumina for Startups Australia.

“Through collaborative interactions, rapid delivery of solutions and prioritising the needs of researchers and entrepreneurs, Illumina Innovation Collective will spearhead genomics innovation at a global level to make a real impact on human health and beyond.”

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Blood-based biomarker can detect sleep deprivation

The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...

Epigenetic signature helps to diagnose rare breast tumour

The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...

New instrument measures cardiovascular disease biomarkers

CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd